NEW LIMITATION CHANGE

TO
Approved for public release, distribution unlimited

FROM
Distribution authorized to U.S. Gov’t. agencies only; Proprietary Info.; Jul 96. Other requests shall be referred to Commander, Army Medical Research and Materiel Command, Attn: MCMR-RMI-S, Fort Detrick, Frederick, MD 21702-5012.

AUTHORITY
USAMRMC, Fort Detrick, MD ltr dtd 11 Mar 1998
GRANT NUMBER DAMD17-94-J-4325

TITLE: The Effects of Electroacupuncture on Cyclophosphamide-Induced Emesis in Ferrets

PRINCIPAL INVESTIGATOR: Lixing Lao, Ph.D.

CONTRACTING ORGANIZATION: University of Maryland at Baltimore
Baltimore, Maryland 21201

REPORT DATE: July 1996

TYPE OF REPORT: Final

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, July 1996). Other requests for this document shall be referred to Commander, U.S. Army Medical Research and Materiel Command, ATTN: MCMR-RMI-S, Fort Detrick, Frederick, MD 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Nausea and vomiting are severe side-effects often associated with cancer chemotherapy and may affect treatment decisions. In order to examine the effects of electroacupuncture (EA) on the emetogenic effect of cyclophosphamide a commonly used chemotherapy agent for breast cancer, ferrets (1.0-2.0 kg) were placed under general anesthesia (isoflurane 5%-oxygen mixture) and were administered logarithmic doses of i.v. cyclophosphamide. A dose of 177 mg/kg produced the maximal number of emetic episodes (23.3±4.0 episodes) with an emetic profile consisting of two phases (first phase 18.8±3.9 episodes; second phase 4.7±1.2 episodes). For treatment, EA was given under general anesthesia followed by i.v. cyclophosphamide (177mg/kg). Various parameters were evaluated and the results indicated that EA (100Hz,1.5V,10 min) effectively treated the first emetic phase induced by cyclophosphamide (9.3±1.8 episodes for the first phase), an effect similar to the antiemetic drug ondansetron. Studies using combination therapy of EA with ondansetron (0.04mg/kg) or metoclopramide (2.24mg/kg) showed a significant reduction in the total number of emetic episodes (p<0.05;p<0.005 respectively). This indicates that EA may be useful as an adjunctive therapy in the treatment of chemotherapy-induced emesis.
Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research involving recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

[Signature] 7-27-91
# TABLE OF CONTENTS

- Front Cover .................................................. 1
- SF298, Report Documentation Page .......................... 2
- Foreword ...................................................... 3
- Table of Contents ............................................. 4
- Introduction .................................................. 6
- Body ..................................................................... 7
- Conclusions ..................................................... 30
- References ..................................................... 31
- Appendix ......................................................... 33
- Bibliography and List of Personnel ........................... 46
FINAL REPORT

Principal Investigator: Lixing Lao, Ph.D., L.Ac.

Grant Number DAMD17-94-J-4325

Title: The Effects of Electroacupuncture on Cyclophosphamide-Induced Emesis in Ferrets

Prepared for: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012
INTRODUCTION

Nausea and vomiting (N/V) are common incidences among patients who have cancer chemotherapy (Coates et al., 1983; Watcha & White, 1992). Antiemetic drugs do not completely block N/V and most often add to the unpleasant effects of treatment (Cubeddu et al., 1990b; D'Olimpia et al., 1985; Watcha & White, 1992). Among the various treatment modalities to reduce N/V, the effect of acupuncture point P6 has been investigated in clinical trials (Aglietti et al., 1990; Dundee, 1991). The clinical studies by Dundee's group indicated that invasive acupuncture combined with antiemetic drug therapy benefited cancer patients in chemotherapy which included cyclophosphamide (Dundee et al., 1989). Other studies conducted by Dundee's group showed that acupressure and transcutaneous electrical stimulation (TENS) of the same acupoints also benefited the patient undergoing chemotherapy (Dundee & Yang, 1990; Dundee et al., 1991). Aglietti's group demonstrated that acupuncture effectively decreased N/V in patients treated with cisplatin (Aglietti, et al., 1990).

Cyclophosphamide is a commonly used agent in chemotherapy for breast cancer and induces emesis in a ferret model (Andrews et al., 1988; Hawthorn et al., 1988). Cyclophosphamide may induce emesis through release of serotonin to stimulate the 5-HT3 receptor in the gastrointestinal tract and the chemoreceptor trigger zone (Fraschini et al., 1991; Hawthorn et al., 1988). The 5-HT3 antagonists such as ondansetron have been shown to be moderately effective antiemetics for cyclophosphamide-induced emesis in ferrets (Andrews et al., 1988) and humans (Clavel et al., 1993; Cubeddu et al., 1990a; Fraschini et al., 1991; Rosso et al., 1991). Side effects have included headache, light-heatedness and transient elevations of hepatic transaminases (Clavel et al., 1993; Cubeddu et al., 1990a; Einhorn et al., 1990; Fraschini et al., 1991; Hesketh & Gandara, 1991; Rosso et al., 1991). The combination dopamine/5-HT3 antagonist metoclopramide has been moderately effective in reducing cyclophosphamide-induced emesis in humans (Clavel et al., 1993). Metoclopramide has been shown to produce adverse extrapyramidal side effects in humans (Sanger, 1990). There is no animal model to study the antiemetic effects of acupuncture, however, our pilot study showed that EA given at acupuncture point P6 reduced morphine-induced emesis by 39-43% (Lao et al., 1995).

Acupuncture has been used to treat a variety of diseases, including pain, in China for thousands of years. According to Traditional Chinese Medicine (TCM), there are 12 primary channels or meridians and 8 additional meridians, each following a directional course along the body. A vital energy known as Qi flows through these meridians and participates in the homeostatic regulation of various body functions. Some 360 points distributed along the meridians serve as both pathognomic signs of disorder and as loci for acupuncture treatments (O'Connor & Bensky, 1981; Stux & Pomeranz, 1987). The meridian flow of Qi can be blocked by any pathogen which results in various symptoms or syndromes. Accordingly, acupuncture treatment involves the insertion of small-gauge needles into specific points as indicated by the nature of the imbalance in order to restore the vital flow of energy through affected meridians (O'Connor & Bensky, 1981; Stux & Pomeranz, 1987). The needles are typically left in place for 20-30 minutes. The effects of acupuncture may be augmented with electrical stimulation (EA) and/or heat (e.g. moxibustion). Side-effects from acupuncture are rare and tend to be associated with violations of sterile procedure and/or negligence on the part of the acupuncturist (Kent & Brondum, 1988; Wright et al., 1991).
A pilot study in our laboratories has shown that the acupuncture technique can be transferred to the ferret by modification of the acupuncture points in humans (Lao et al., 1995). This study showed that EA significantly reduced the number of emetic episodes induced by morphine (Lao et al., 1995). In humans, the acupuncture point Neiguan (P6) is located on the forearm, 2 units directly above the midpoint of the transverse crease of the wrist (the distance between cubital and carpal creases is 12 units), between the tendons of the flexor carpi radialis and the palmaris longus muscles. Below this point is the median nerve (O'Connor & Bensky, 1981). The equivalent point in ferrets had been located in our pilot study (Lao et al., 1995).

The specific aims of the present study are:

1. To determine the emetogenic effect of cyclophosphamide in the ferret.
2. To determine the most effective EA conditions and to evaluate the effect of EA in reducing cyclophosphamide-induced emesis in the ferret.
3. To test the antiemetic effects of ondansetron, metoclopramide, and droperidol against cyclophosphamide-induced emesis in the ferret and to compare these effects to EA.
4. To evaluate that an EA-drug combination is more efficacious as an antiemetic against cyclophosphamide in the ferret than either treatment alone.

BODY

Ferrets were castrated males, 1.0-2.0 kg in weight and from the Triple F Farm, Sayre, PA. Ferrets were made unconscious by general anesthesia (Isoflurane 5%-O₂ mixture) to restrain them for acupuncture treatment. For testing, ferrets were anesthetized with isoflurane 5%-O₂ mixture while contained in a 20 gallon glass aquarium box with a removable plastic cover. The anesthetic gas was delivered from a vaporizer (Fortec), calibrated for isoflurane, through polyethylene tubing into the box and was scavenged out using a vacuum tubing vented to the outside air. Each ferret was removed after loss of righting (2-5 min) and immediately weighed. For EA, each animal was maintained under isoflurane 2.5%-O₂ anesthesia delivered from a second vaporizer through a small nose cone. For EA treatment, the equivalent acupuncture point P6 in the ferret was located at the forepaws (Lao et al., 1995). After needle insertion (disposable needle, gauge # 34, diameter 0.22 mm, length 1 in., depth of 0.3-0.5 in.), the stimulator's electrodes (Grass) were attached to the end of the needles and electrical stimulation was applied (the EA parameters will be described in detail later). The frequency and voltage of stimulation were monitored by an oscilloscope (Tektronix).
Specific Aim #1.

Ferrets were given i.v. cyclophosphamide at log doses of 56, 100, 177, and 237 mg/kg (n=6 for all doses except 237 mg/kg where n=2). For the i.v. route of administration, cyclophosphamide injections were made into the cephalic vein on the dorsal aspect of a front paw using a rubber tourniquet and a 3 or 5 ml syringe with a 25 G needle while the ferret was under general anesthesia. The forepaw was shaved for ease of vein location. Intravenous puncture was confirmed by aspirating a small volume of blood into the syringe and injections confirmed by lack of resistance to the syringe plunger. After injection, each ferret was placed into an individual compartment (60 x 60 x 38 cm²) of a cage rack holding six compartments having wire mesh floors elevated to the height of door threshold and modified with a plexiglass front door for ease of viewing. Complete recovery from anesthesia occurred in all ferrets within 3-10 min. Emetic action of the animal was observed and the onset time of emesis was recorded. The number of episodes of retching and vomiting were also recorded along with the prodromal signs of nausea: salivation, head shake, lip lick, walking backwards, posturing, sedation, and slit eyes (Wynn et al., 1993). Statistical analysis was done using Student’s two-way t-test with a p<0.05 considered significant. After each experiment, the ferrets were sacrificed using carbon dioxide (CO₂). This study (amended 11/29/93) has been approved by the Institutional Animal Care and Use Committees (Ref. #134200-039301 and #93-04-01) at the School of Medicine and the Dental School, University of Maryland at Baltimore.

The results indicated that the dose of 177 mg/kg produced the maximal number of emetic episodes (23.3±4.0 emetic episodes; Table 1; Appendix; Wong et al., 1996). The dose of 237 mg/kg was not chosen for further experiments since it had toxic effects. Cyclophosphamide induced emesis in a dose-dependent manner producing two distinct emetic phases that were separated by a one hour time period (Fig. 1). The first phase resulted in a mean of 18.6±3.9 emetic episodes and the second phase produced 4.7±1.2 emetic episodes. These two phases were used to compare the effects of EA, antiemetic drug therapy, and combination therapy.

Table 1. Emetogenic Effect of Cyclophosphamide by Dose in Ferrets

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>No. Vomiting/N</th>
<th>Mean±S.E. Emetic Episodes</th>
<th>Mean±S.E. Retches</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclophosphamide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>56</td>
<td>4/6</td>
<td>2.2±0.9</td>
<td>2.8±1.9</td>
</tr>
<tr>
<td>100</td>
<td>5/6</td>
<td>7.3±3.2</td>
<td>30.5±17.5</td>
</tr>
<tr>
<td>177</td>
<td>8/8</td>
<td>23.3±4.0</td>
<td>85.3±20.4</td>
</tr>
<tr>
<td>237</td>
<td>2/2</td>
<td>23.5±7.5</td>
<td>62.5±38.5</td>
</tr>
</tbody>
</table>
Fig. 1. Emetic Profile for Cyclophosphamide (177 mg/kg)
Specific Aim #2.

Changes in the frequency (5 and 100Hz), intensity (1.5 and 3V), and duration (5, 10, and 20 min) of electrical stimulation were evaluated (n=6/group; Table 2, Figs. 2-6). EA was administered followed immediately by i.v. cyclophosphamide (177 mg/kg). Our results indicated that EA at 100 Hz, 1.5V, 10 min produced the most beneficial antiemetic effect as compared to other parameters. Using these stimulation parameters, EA was more effective against the first emetic phase with a mean of 9.3±1.8 emetic episodes (Table 2, Fig. 2). This resulted in a 50% decrease in emetic episodes for the first phase. For all tested parameters, there was no significant reduction in the total number of emetic episodes as compared to control.

Table 2. Electroacupuncture Against Cyclophosphamide in Ferrets

<table>
<thead>
<tr>
<th>EA Parameters (Frequency, Intensity, Duration)</th>
<th>N</th>
<th>Mean±S.E. Emetic Episodes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle</td>
<td>8</td>
<td>18.6±3.9</td>
</tr>
<tr>
<td>5Hz, 3V, 10 min</td>
<td>6</td>
<td>10.3±1.9</td>
</tr>
<tr>
<td>100Hz, 1.5V, 20 min</td>
<td>6</td>
<td>16.5±4.6</td>
</tr>
<tr>
<td>100Hz, 1.5V, 5 min</td>
<td>6</td>
<td>11.8±4.3</td>
</tr>
<tr>
<td>100Hz, 3.0V, 10 min</td>
<td>6</td>
<td>13.2±5.3</td>
</tr>
<tr>
<td>100Hz, 1.5V, 10 min</td>
<td>6</td>
<td>9.3±1.8</td>
</tr>
<tr>
<td>Sham</td>
<td>6</td>
<td>14.0±2.7</td>
</tr>
<tr>
<td>Placebo</td>
<td>6</td>
<td>12.2±3.0</td>
</tr>
<tr>
<td>Mean±S.E. Emetic Episodes</td>
<td></td>
<td>First Phase¹</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4.7±1.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10.7±2.5*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8.3±1.1*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8.7±0.9*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7.7±2.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10.0±2.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7.8±1.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10.5±1.7*</td>
</tr>
</tbody>
</table>

(*p≤0.05 compared to vehicle control values; ¹Time 0 to 70 min; ²Time 130 to 240 min)
Fig. 2. Emetic Profile for EA (100Hz, 1.5V, 10 min)
Fig. 3. Emetic Profile for EA (100Hz, 3V, 10 min)
Fig. 4. Emetic Profile for EA (5Hz, 3V, 10 min)
Fig. 5. Emetic Profile for EA (100Hz, 1.5V, 20 min)
Fig. 6. Emetic Profile for EA (100Hz, 1.5V, 5 min)
After the evaluation of the EA parameters, controlled experiments were done to compare the effectiveness of EA (100Hz, 1.5V, 10 min) against cyclophosphamide-induced emesis with respect to sham acupuncture and non-treatment. In the sham acupuncture group, a non-acupuncture point (dummy point) was used at the elbow area (Dundee, 1991), and no electrical stimulation was applied. The results indicated a mean first phase of 14.0±2.7 emetic episodes (Table 2, Fig. 7). In the placebo (non-treatment) group, animals received the same protocol as the acupuncture group except that the acupuncture needles were taped on the skin of the animal (rather than inserted) and did not have electrical stimulation. This resulted in a mean first phase of 12.2±3.0 emetic episodes (Table 2, Fig. 8). No statistical significance among these three groups (EA vs Sham: p=0.1; EA vs Placebo: p=0.2). However, the results showed trend that EA group has lowest episodes in the first phase of emesis induced by cyclophosphamide compared to sham and placebo. In order to assess any adverse effects associated with this type of therapy, animals were treated with acupuncture alone (n=6) without injection of cyclophosphamide. Any unusual animal behavior changes would be observed, recorded and analyzed, such as seizures, dry mouth, salivation, moving head back and forth, fine tremor, or sedateness. None of these unusual behaviors were observed from the EA treatment.

Specific Aim #3.

Three antiemetic drugs were used for the treatment of cyclophosphamide-induced emesis: ondansetron, metoclopramide, and droperidol. Using log doses, the antiemetic drugs were administered i.v. immediately following cyclophosphamide injection (177 mg/kg). Ondansetron reduced emetic episodes by 0, 42, and 9% (0.04, 0.07, and 0.13 mg/kg) (Table 3, Figs. 9-11; Wong et al., 1996). This drug produced an emetic profile similar to acupuncture in which it was able to effectively treat the first phase of emesis but increased the number of episodes in the second phase. Metoclopramide reduced emetic episodes by 48, 65, and 98% (2.24, 4.08, 7.07 mg/kg) (Table 3, Figs. 12-14; Wong et al., 1996). Metoclopramide significantly reduced the number of emetic episodes in the first phase and completely prevented emesis in the second phase at a dose of 7.07 mg/kg. Droperidol resulted in a 24, 16, and 38% reduction (0.25, 0.45, 0.79 mg/kg) in which it was able to significantly reduce the first emetic phase but increased the number of emetic episodes in the second phase (Table 3, Fig. 15-17).

Specific Aim #4.

Combination therapy was evaluated in ferrets (n=6) who were first treated with EA (100 Hz, 1.5V, 10 min) since it was effective against the first emetic phase. This was followed by injection with cyclophosphamide (177 mg/kg). The antiemetic drug was then given i.v. immediately following cyclophosphamide. Ondansetron (0.04 mg/kg) combined with EA significantly reduced the total number of emetic episodes (11.8±2.2) and the number of emetic episodes in the first phase (Table 4). Ondansetron at a dose of 0.02 mg/kg significantly increased the second emetic phase (Table 4). EA and metoclopramide (2.24 mg/kg) significantly reduced the total number of emetic episodes (6.2±2.0). Metoclopramide at this dose and also at a lower dose of 1.26 mg/kg significantly reduced the number of emetic episodes in the first phase (Table 4). Combination of EA with droperidol (0.25 and 0.45 mg/kg) significantly reduced the number of emetic episodes in the first emetic phase in which it significantly increased the second phase at the dose of 0.45 mg/kg (Table 4).
Fig. 7. Emetic Profile for Sham Acupuncture

Mean No. Emetic Episodes

Time (min)
Fig. 8. Emetic Profile for Placebo Acupuncture
### Table 3. Dose Response of Antiemetics Against Cyclophosphamide in Ferrets

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>N</th>
<th>First Phase</th>
<th>Second Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle</td>
<td>8</td>
<td>18.6±3.9</td>
<td>4.7±1.2</td>
</tr>
<tr>
<td>Ondansetron</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.04</td>
<td>5</td>
<td>12.2±3.7</td>
<td>15.4±2.8**</td>
</tr>
<tr>
<td>0.07</td>
<td>5</td>
<td>0.4±0.4**</td>
<td>11.0±2.1*</td>
</tr>
<tr>
<td>0.13</td>
<td>5</td>
<td>2.8±1.7*</td>
<td>18.2±3.5**</td>
</tr>
<tr>
<td>Metoclopramide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.24</td>
<td>5</td>
<td>3.2±2.7*</td>
<td>8.2±3.1</td>
</tr>
<tr>
<td>4.08</td>
<td>5</td>
<td>3.6±1.9*</td>
<td>3.8±1.3</td>
</tr>
<tr>
<td>7.07</td>
<td>5</td>
<td>0.4±0.2**</td>
<td>0.0±0.0</td>
</tr>
<tr>
<td>Droperidol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.25</td>
<td>5</td>
<td>5.8±2.6*</td>
<td>11.4±2.7*</td>
</tr>
<tr>
<td>0.45</td>
<td>5</td>
<td>12.0±2.3</td>
<td>6.8±2.2</td>
</tr>
<tr>
<td>0.79</td>
<td>5</td>
<td>5.6±3.1*</td>
<td>8.8±1.7</td>
</tr>
</tbody>
</table>

(*p<0.05, **p<0.005 compared to vehicle control values; \(^1\) Time 0 to 70 min; \(^2\) Time 130 to 240 min)
Fig. 9. Emetic Profile for Ondansetron (0.04 mg/kg)
Fig. 10. Emetic Profile for Ondansetron (0.07 mg/kg)
Fig. 12. Emetic Profile for Metoclopramide (2.24 mg/kg)
Fig. 13. Emetic Profile for Metoclopramide (4.08 mg/kg)
Fig. 14. Emetic Profile for Metoclopramide (7.07 mg/kg)
Fig. 15. Emetic Profile for Droperidol (0.25 mg/kg)
Fig. 16. Emetic Profile for Droperidol (0.45 mg/kg)
Fig. 17. Emetic Profile for Droperidol (0.79 mg/kg)
Table 4. Combination of Electroacupuncture and Antiemetic Drug Therapy Against Cyclophosphamide in Ferrets

<table>
<thead>
<tr>
<th>EA + Drug (mg/kg) (100 Hz, 1.5V, 10 min)</th>
<th>N</th>
<th>First Phase</th>
<th>Second Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle</td>
<td>8</td>
<td>18.6±3.9</td>
<td>4.7±1.2</td>
</tr>
<tr>
<td>EA + Ondansetron (0.02 mg/kg)</td>
<td>6</td>
<td>14.8±3.4</td>
<td>10.8±2.3*</td>
</tr>
<tr>
<td>EA + Ondansetron (0.04 mg/kg)</td>
<td>6</td>
<td>1.7±1.1**</td>
<td>8.7±1.8</td>
</tr>
<tr>
<td>EA + Metoclopramide (1.26 mg/kg)</td>
<td>6</td>
<td>6.5±1.1*</td>
<td>5.3±1.7</td>
</tr>
<tr>
<td>EA + Metoclopramide (2.24 mg/kg)</td>
<td>6</td>
<td>0.7±0.5**</td>
<td>5.3±1.5</td>
</tr>
<tr>
<td>EA + Droperidol (0.25 mg/kg)</td>
<td>6</td>
<td>7.0±1.3*</td>
<td>6.2±1.3</td>
</tr>
<tr>
<td>EA + Droperidol (0.45 mg/kg)</td>
<td>6</td>
<td>1.7±0.9**</td>
<td>12.2±1.4**</td>
</tr>
</tbody>
</table>

(*p<0.05, **p<0.005 compared to vehicle control values; 'Time 0 to 70 min; 'Time 130 to 240 min)
CONCLUSIONS

The present study showed that cyclophosphamide produced a biphasic emetic response in the ferret. EA (100 Hz, 1.5V, 10 min) was effective in treating the first emetic phase induced by cyclophosphamide. It had an effect similar to the antiemetic drug ondansetron which also treats the first phase (increases the second phase). Combination therapy of EA and an antiemetic drug (ondansetron 0.04 mg/kg; metoclopramide 2.24 mg/kg) produced the most beneficial effect by significantly reducing the total number of emetic episodes as compared to either treatment alone. Although this was shown to be true for the suboptimal 0.04-mg/kg ondansetron and 2.24-mg/kg metoclopramide dose levels, there is the possibility of no additional antiemetic benefit over that of drug therapy alone at the more effective drug dose levels. However, the results suggested that at lower drug dose levels, EA would be useful as an adjunctive therapy in the treatment of chemotherapy-induced emesis. The results also led to a decrease in the variables evaluated (the number of parameters of EA tested and the number of doses of antiemetic drugs used were sufficient) which decreased a few groups of animals used for this protocol. Acupuncture alone was also examined in which there was no significant adverse effects observed. The significance of this study is that acupuncture as an adjunctive therapy may lead to a decrease in the dose and side effects of the antiemetic drugs which may improve the quality of life for the breast cancer patient. Modern antiemetics have proven to be of use in the prevention of chemotherapy induced N/V; however, a subgroup of patients continues to have N/V. Future clinical studies are necessary to evaluate acupuncture as an adjunctive therapy for the treatment of nausea and vomiting in the breast cancer patient.
REFERENCES


Cyclophosphamide (177 mg/kg i.v., n=8) produced a biphasic emetic response in the ferret with a mean (±S.E.) of 23.3±4.0 emetic episodes during a four hour observation period. The emetic profile of cyclophosphamide showed a first phase with 18.6±3.9 episodes and a second phase with 4.7±1.2 episodes. Ondansetron (0.07 and 0.13 mg/kg i.v.) and droperidol (0.25 and 0.79 mg/kg i.v.) significantly reduced the number of emetic episodes in the first phase. Metoclopramide (2.24, 4.08, and 7.07 mg/kg i.v.) also significantly reduced the number of emetic episodes in the first phase and the dose of 7.07 mg/kg completely prevented emetic episodes in the second phase. In addition, ondansetron treated ferrets (0.04, 0.07, and 0.13 mg/kg i.v.) had a significant increase in the number of emetic episodes in the second phase.

Keywords: Cyclophosphamide, emesis, ondansetron, metoclopramide, droperidol, ferret

Breast cancer patients are often treated with an adjuvant chemotherapy regimen which includes cyclophosphamide (2,3,8). This alkylating agent has a high potential for inducing nausea and vomiting which adds to the difficult nature of cancer treatment (5,8). Unlike many chemotherapy agents, emesis associated with cyclophosphamide may often extend up to 72 hours (2). Cyclophosphamide induces emesis in a ferret model (1,6) possibly through release of serotonin to stimulate the 5-HT₃ receptor in the gastrointestinal tract and the chemoreceptor trigger zone (5,6). The serotonin (5-HT₃) receptor antagonists have been shown to be effective antiemetics for cyclophosphamide-induced emesis in ferrets (1) and humans (2,3,5,8). Side effects have included headache, light-headedness and transient elevations of hepatic transaminases.
Metoclopramide, a dopamine (D₂) receptor/5-HT₃ receptor antagonist, has been moderately effective in reducing cyclophosphamide-induced emesis in humans (2). However, metoclopramide has been shown to produce adverse extrapyramidal reactions in humans (9). The dopamine (D₂) antagonist droperidol has not been tested against cyclophosphamide-induced emesis. The purpose of this study was to further examine the characteristics of the emetic effects of intravenous cyclophosphamide in the ferret and to evaluate the antiemetic efficacy of ondansetron, a selective 5-HT₃ antagonist, metoclopramide, and droperidol.

MATERIAL AND METHODS

Ferrets (fitch or albino) were castrated males, 1.0-2.0 kg in weight (Triple F Farm, Sayre, PA), and were housed three to a cage on a twelve hour light cycle. Food (Lab Diet) and water were given ad libitum. Ferrets were used only one time. For testing, ferrets were placed under general anesthesia (isoflurane 5-%-O₂ mixture) delivered from a vaporizer (Fortec), calibrated for isoflurane, through polyethylene tubing into an anesthesia chamber. The anesthetic was scavenged out using a vacuum tubing vented to the outside air. Each ferret was removed after loss of righting (2-5 min) and immediately weighed. For the intravenous (i.v.) injections, each animal was maintained under general anesthesia (isoflurane 2.5-%-O₂) with a second vaporizer (Fortec) through a small nose cone. Both forepaws were shaved for ease of vein location. Cyclophosphamide monohydrate (Sigma) was dissolved in a small amount of absolute alcohol (200 mg/400 microliters) immediately prior to injection. Saline (154 mM) was used to dilute the cyclophosphamide to a final concentration of 100 mg/mL. Cyclophosphamide injections were made into the cephalic vein on the dorsal aspect of a front paw using a rubber tourniquet and a 3 or 5 ml syringe with a 25 G needle. Intravenous puncture was confirmed by aspiration of a small
volume of blood into the syringe, and the injections were confirmed by the lack of resistance to the syringe plunger. The following log doses of cyclophosphamide were tested: 56 (n=6), 100 (n=6), 177 (n=8), and 237 (n=2) mg/kg. For administration of the antiemetic drugs (n=5/dose), a second i.v. injection was made into the opposite forepaw within one minute following cyclophosphamide (177 mg/kg) injection. This dose of i.v. cyclophosphamide was chosen for the subsequent antiemetic experiments since it produced the maximal number of emetic episodes without toxicity. Ondansetron (Glaxo, 2 mg/mL), metoclopramide (A.H. Robbins, 5 mg/mL), and droperidol (American Regent, 2.5 mg/mL) were obtained from the University of Maryland Hospital pharmacy as the commercial preparations. The doses of the antiemetic drugs were given as follows: ondansetron, 0.04, 0.07, 0.13 mg/kg; metoclopramide, 2.24, 4.08, 7.07 mg/kg; and droperidol, 0.25, 0.45, 0.79 mg/kg.

After injection, each ferret was then placed into an individual compartment (60 x 60 x 38 cm²) of a six-compartment cage rack with wire mesh floors elevated to the height of the door threshold (modified with a plexiglass front door) for observation. Each ferret was observed for four hours after recovering from anesthesia (3-10 min). The time and number of each episode of retching and vomiting were recorded. Retching was counted as the rhythmic contraction of the abdomen without expulsion of material, and emesis as a contraction with the expulsion of solid or liquid. Total emetic episodes were averaged for each group (±S.E.) and the effect of treatment was calculated as the percent reduction of emetic episodes as previously described (10). Differences between the mean number of emetic episodes for the treatment groups compared to the cyclophosphamide group (177 mg/kg) were compared by Student’s two-tail t-test with a p ≤ 0.05 considered significant. This study was approved by the Institutional Animal Care and Use
Committees at the School of Medicine and the Dental School, University of Maryland at Baltimore.

RESULTS

The dose effect profile of cyclophosphamide-induced emesis in the ferret after intravenous injection is shown in Table 1. The dose of 237 mg/kg produced oedema around the eyes and erythema in the facial area. This was interpreted as toxicity and only two animals were tested at this dose. Evaluation of the duration of emetic episodes using time bins of 10 min revealed two distinct phases over the entire duration of effect for the doses of 100 and 177 mg/kg. These two emetic phases for the dose of 177 mg/kg are shown in Figure 1. The first phase had a mean onset time of 1.1±0.5 min and duration of 70 min. The second phase occurred 60 min after the termination of the first phase.

On the basis of the total number of emetic episodes, ondansetron reduced cyclophosphamide-induced emesis (177 mg/kg) by 0, 42, and 9% (0.04, 0.07, 0.13 mg/kg), metoclopramide by 48, 65 and 98% (2.24, 4.08, 7.07 mg/kg), and droperidol by 24, 16, and 38% (0.25, 0.45, 0.79 mg/kg). Significant differences in the mean number of total emetic episodes were found for metoclopramide at doses of 4.08 mg/kg (p<0.05) and 7.07 mg/kg (p<0.005) compared to vehicle control. All three antiemetic drugs (ondansetron at 0.07 and 0.13 mg/kg; metoclopramide at 2.24, 4.08, and 7.07 mg/kg; and droperidol at 0.25 and 0.79 mg/kg) significantly reduced the number of emetic episodes in the first phase (Table 2). Metoclopramide at 7.07 mg/kg completely prevented the second emetic phase, whereas both ondansetron and droperidol treated ferrets had a significant increase in the number of emetic episodes in this phase (Table 2).
DISCUSSION

A previous literature report evaluating cyclophosphamide at two dosages and various routes of administration showed that this chemotherapeutic drug produced emesis in the ferret (6). At an i.v. dose of 100 mg/kg, this study reported a mean number (±S.E.) of 0.4±0.2 emetic episodes and 4.6±2.4 retches during a four hour observation period (6). However, in our study, we observed 7.3±3.2 emetic episodes and 30.5±17.5 retches at 100 mg/kg (i.v.) with a four hour observation period (Table 1). The only methodological differences were in our use of direct i.v injection and in our preparation of the cyclophosphamide, using a final concentration of 100 mg/mL which is commonly used in chemotherapy patients. In our study, a dose of 177 mg/kg produced two phases of emesis (Fig. 1).

The early onset emetic phase induced by cyclophosphamide may possibly be due to direct central effects involving the 5-HT₃ or D₂ receptor. The antiemetic drugs ondansetron (a 5-HT receptor antagonist) and droperidol (D₂ receptor antagonist) were only able to significantly reduce the number of emetic episodes in this phase while increasing the second phase (Table 2). Furthermore, the emetic profile of cyclophosphamide for the first phase (Fig. 1) showed a decline in episodes over time which may be indicative of the clearance of the drug from the site of action.

The second emetic phase induced by cyclophosphamide may involve a different mechanism. Metoclopramide, a D₂/5-HT₃ antagonist, was the only effective antiemetic drug that could reduce the number of emetic episodes in this phase (Table 2). However, the high dose of metoclopramide (7.07 mg/kg) did produce adverse central nervous system effects (eg. mean±S.E. of 82.6±16.6 head shakes as compared to control, 19.3±5.9). The significant increase in emetic episodes in the second phase seen with ondansetron and droperidol (Table 2) may be due to the elimination of these drugs in the tissues, thus allowing for the emetogenic effects of cyclophosphamide to predominate. Further
studies are necessary to examine the different mechanisms that may be involved in the biphasic emetogenic response of cyclophosphamide. Since patients may vomit for at least two days (or more) after cyclophosphamide, future studies in the ferret will also need to utilize longer observation periods in order to evaluate similarities with what occurs in patients.

ACKNOWLEDGEMENTS

We thank Greg Haynes for his expert technical assistance. We also thank Marilyn Commer for preparation of the manuscript. Support provided by the U.S. Army Breast Cancer Research Program #DAMD17-94-J-4325.
REFERENCES


Table 1. Emetogenic Effect of Cyclophosphamide by Dose in Ferrets

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>No. Vomiting/N</th>
<th>Mean±S.E. Emetic Episodes</th>
<th>Mean±S.E. Retches</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclophosphamide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>56</td>
<td>4/6</td>
<td>2.2±0.9</td>
<td>2.8±1.9</td>
</tr>
<tr>
<td>100</td>
<td>5/6</td>
<td>7.3±3.2</td>
<td>30.5±17.5</td>
</tr>
<tr>
<td>177</td>
<td>8/8</td>
<td>23.3±4.0</td>
<td>85.3±20.4</td>
</tr>
<tr>
<td>237</td>
<td>2/2</td>
<td>23.5±7.5</td>
<td>62.5±38.5</td>
</tr>
</tbody>
</table>
Table 2. Dose Response of Antiemetics Against Cyclophosphamide in Ferrets

<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>N</th>
<th>First Phase&lt;sup&gt;1&lt;/sup&gt;</th>
<th>Second Phase&lt;sup&gt;2&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle</td>
<td>8</td>
<td>18.6±3.9</td>
<td>4.7±1.2</td>
</tr>
<tr>
<td>Ondansetron</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.04</td>
<td>5</td>
<td>12.2±3.7</td>
<td>15.4±2.8**</td>
</tr>
<tr>
<td>0.07</td>
<td>5</td>
<td>0.4±0.4**</td>
<td>11.0±2.1*</td>
</tr>
<tr>
<td>0.13</td>
<td>5</td>
<td>2.8±1.7*</td>
<td>18.2±3.5**</td>
</tr>
<tr>
<td>Metoclopramide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.24</td>
<td>5</td>
<td>3.2±2.7*</td>
<td>8.2±3.1</td>
</tr>
<tr>
<td>4.08</td>
<td>5</td>
<td>3.6±1.9*</td>
<td>3.8±1.3</td>
</tr>
<tr>
<td>7.07</td>
<td>5</td>
<td>0.4±0.2**</td>
<td>0.0±0.0</td>
</tr>
<tr>
<td>Droperidol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.25</td>
<td>5</td>
<td>5.8±2.6*</td>
<td>11.4±2.7*</td>
</tr>
<tr>
<td>0.45</td>
<td>5</td>
<td>12.0±2.3</td>
<td>6.8±2.2</td>
</tr>
<tr>
<td>0.79</td>
<td>5</td>
<td>5.6±3.1*</td>
<td>8.8±1.7</td>
</tr>
</tbody>
</table>

(*p≤0.05, **p≤0.005 compared to vehicle control values; <sup>1</sup>Time 0 to 70 min; <sup>2</sup>Time 130 to 240 min)
Fig. 1. Emetic profile of i.v. cyclophosphamide at 177 mg/kg. Two distinct phases of emesis are present.
Abstracts:


Lao, L., Use of Acupuncture in Small Mammals, For presentation at the Eighth Small Mammals Veterinary Conference, Baltimore, Maryland, August, 1996.

Publications:


Personnel:

L. Lao, Ph.D., L.Ac., Principle Investigator
R.H. Wong, D.D.S., Investigator
R.L. Wynn, Ph.D., Investigator
B. Berman, M.D., Investigator
A. Carter, Laboratory Technician
G. Haynes, Laboratory Technician
T. Folks, Secretary
DOSE-RESPONSE OF CYCLOPHOSPHAMIDE-INDUCED EMESIS IN THE FERRET. R.L. Wynn, A. Carter, R. Meszler*, L. Lao, B.M. Berman and R.H. Wong. Department of Family Medicine, School of Medicine, and Departments of Anatomy and Pharmacology, Dental School, University of Maryland, Baltimore, MD 21201

Nausea and vomiting are severe side-effects often associated with cancer chemotherapy and may affect treatment decisions. Cyclophosphamide is a commonly used chemotherapy agent for breast cancer and induces emesis in the ferret. In order to examine the emetogenic effect of cyclophosphamide, ferrets (1.0-1.8 kg) were placed under general anesthesia (isoflurane 5%-O<sub>2</sub> mixture) and were administered logarithmic doses of i.v. cyclophosphamide. The mean number (±SE) of emetic episodes and retches were: 2.2±0.9 episodes and 2.8±1.9 retches at 56 mg/kg, 7.3±3.2 and 30.5±17.5 at 100 mg/kg, 23.3±4.0 and 85.3±20.4 at 177 mg/kg, and 23.5±7.5 and 62.5±38.5 at 237 mg/kg. In addition, various antiemetics were given i.v. immediately following cyclophosphamide injection. Ondansetron reduced emetic episodes by 0% and 43% (0.04 and 0.07 mg/kg), metoclopramide by 65% and 98% (4.08 and 7.07 mg/kg), and droperidol by 16% and 24% (0.45 and 0.25 mg/kg). These results indicate that cyclophosphamide induces emesis in a dose-dependent manner and may be useful in evaluating conventional and complementary therapies for the treatment of chemotherapy-induced emesis. Support provided by the U.S. Army Breast Cancer Research Program #DAMD17-94-J-4325.
ABBREVIATION

SESSION TITLE: USE OF ACUPUNCTURE IN SMALL MAMMALS

Lixing Lao, Ph.D.

Nausea and vomiting are severe side-effects often associated with cancer chemotherapy and may affect treatment decisions. Cyclophosphamide is a commonly used chemotherapy agent for breast cancer and induces emesis in the ferret. In order to examine the effects of electroacupuncture (EA) on the emetogenic effect of cyclophosphamide, ferrets (1.0-1.8 kg) were placed under general anesthesia (isoflurane 5%-O₂ mixture) and were administered logarithmic doses of i.v. cyclophosphamide. A dose of 177 mg/kg produced the maximal number of emetic episodes (23.3±4.0 episodes) with an emetic profile consisting of two phases (first phase 18.6±3.9 episodes; second phase 4.7±1.2 episodes). For treatment, EA was given under general anesthesia followed by i.v. cyclophosphamide (177 mg/kg). Various parameters were evaluated and the results indicated that EA (100 Hz, 1.5V, 10 min) effectively treated the first emetic phase induced by cyclophosphamide (9.3±1.8 episodes for the first phase). EA had an effect similar to the antiemetic drug ondansetron which also treated the first phase. Preliminary studies using combination therapy of EA and metoclopramide (2.24 mg/kg) showed a significant reduction in the number of emetic episodes (p<0.005). This study indicates that EA would be useful as an adjunctive therapy in the treatment of chemotherapy-induced emesis in the ferret.
MEMORANDUM FOR Administrator, Defense Technical Information Center, ATTN: DTIC-OCP, Fort Belvoir, VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for the following contracts. Request the limited distribution statement for these contracts be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

<table>
<thead>
<tr>
<th>Contract Number</th>
<th>Accession Document Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAMD17-94-J-4256</td>
<td>ADB221974</td>
</tr>
<tr>
<td>DAMD17-94-J-4325</td>
<td>ADB225249</td>
</tr>
<tr>
<td>95MM5533</td>
<td>ADB225872</td>
</tr>
</tbody>
</table>

2. Point of contact for this request is Ms. Betty Nelson at DSN 343-7328 or email: betty_nelson@ftdetrck-ccmail.army.mil.

FOR THE COMMANDER:

PHYLIS M. RINEHART
Deputy Chief of Staff for Information Management

1/24/2000